According to DelveInsight, the post-surgical pain therapeutics market is anticipated to grow substantially due to the increasing number of surgical procedures, the rising patient population experiencing post-surgical pain, advancements in research and development of new drugs, and the introduction of emerging pipeline therapies.
DelveInsight’s “Post-Surgical Pain Market Insights, Epidemiology, and Market Forecast 2032” report delivers an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the Post-Surgical Pain market size, share, trends, and growth opportunities in the seven major markets (7MM) (i.e., the United States, EU4 (Germany, Spain, Italy, France), the United Kingdom and Japan).
The Post-Surgical Pain market report covers emerging drugs, current treatment practices, market share of individual therapies, and current & forecasted market size from 2019 to 2032. It also evaluates the current treatment practice/algorithm, key drivers & barriers impacting the market growth, and unmet medical needs to curate the best of the opportunities and assess the underlying potential of the market.
Post-Surgical Pain Overview
Post-surgical pain, also known as postoperative pain, is a common and expected outcome following surgical procedures. Effective management of this pain is crucial for patient recovery, comfort, and overall outcomes.
Post-surgical pain can vary in intensity and duration depending on the type of surgery, the patient’s health condition, and individual pain tolerance. It typically arises from tissue damage, inflammation, and sometimes nerve injury caused during surgery.
Post-Surgical Pain Market Outlook
Postoperative pain management aims to not only reduce pain intensity but also to enhance patient comfort and improve postoperative outcomes. Pharmacologic therapies for pain include drugs from several classes. Analgesics for pain relief include opioids, nonsteroidal anti-inflammatory drugs (NSAIDs), and acetaminophen. Providers may also manage acute pain with benzodiazepines, muscle relaxants, antidepressants, alpha-2 agonists, gamma-aminobutyric acid agonists, and cannabinoids. Additionally, topical agents such as capsaicin and lidocaine are utilized.
NSAIDs are an effective choice for pain management after surgical procedures. However, before surgeons prescribe NSAIDs instead of opioids, it is crucial to understand their potential postoperative complications. NSAIDs offer anti-inflammatory, antipyretic, analgesic, and thrombotic effects by inhibiting the cyclooxygenase enzymes COX-1 and COX-2.
Post-Surgical Pain Epidemiology Assessment
The epidemiology section provides insights into the historical, current, and forecasted epidemiology trends in the seven major countries (7MM) from 2019 to 2032. It helps to recognize the causes of current and forecasted epidemiology trends by exploring numerous studies and research. The epidemiology section also provides a detailed analysis of diagnosed and prevalent patient pool, future trends, and views of key opinion leaders.
Up to 88% of patients may suffer post-operative pain, and of those, 34-62% will likely describe it as moderate to severe.
The Report Covers the Post-Surgical Pain Epidemiology, Segmented as –
-
Total number of surgical procedures in the 7MM
-
Total incident cases of Post-surgical pain in the 7MM
-
Severity-specific incident cases of Post-surgical pain in the 7MM
Post-Surgical Pain Drugs Uptake and Pipeline Development Activities
The drug uptake section focuses on the uptake rate of potential drugs recently launched in the Post-Surgical Pain market or expected to be launched during the study period. The analysis covers the Post-Surgical Pain market uptake by drugs, patient uptake by therapies, and sales of each drug. Moreover, the therapeutics assessment section helps understand the drugs with the most rapid uptake and the reasons behind the maximal use of the drugs. Additionally, it compares the drugs based on market share.
The report also covers the Post-Surgical Pain pipeline development activities. It provides valuable insights about different therapeutic candidates in various stages and the key companies involved in developing targeted therapeutics. It also analyses recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies.
Learn How the Post-Surgical Pain Market Will Evolve and Grow by 2032 @ https://www.delveinsight.com/sample-request/post-surgical-pain-market
Post-Surgical Pain Treatment Market
Postoperative pain management aims to reduce pain intensity, enhance patient comfort, and improve postoperative outcomes. Pharmacologic therapies for pain include a variety of drug classes. Pain-relieving analgesics encompass opioids, nonsteroidal anti-inflammatory drugs (NSAIDs), and acetaminophen. Acute pain management may also involve benzodiazepines, muscle relaxants, antidepressants, alpha-2 agonists, gamma-aminobutyric acid agonists, and cannabinoids. Additionally, topical agents such as capsaicin and lidocaine are used.
Current treatments for postoperative pain include approved drugs such as Anjeso, Dextenza, and Inveltys in the categories of NSAIDs and corticosteroids. The market also features approved opioid medications, including Dsuvia, which was approved in 2018 in the US and the EU. Other approved drugs used for postoperative pain include Exparel and others.
Several major pharmaceutical and biotech companies are actively working in the post-surgical pain therapeutics market to further enhance treatment options.
Leading Companies in the Post-Surgical Pain Therapeutics Market Include: AbbVie (Allergan), Heron Therapeutics, Cali Biosciences, Acadia Pharmaceuticals, Virpax Pharmaceuticals, GlaxoSmithKline Plc, Pacira Pharmaceuticals Inc., Johnson & Johnson (Janssen Pharmaceuticals), AFT Pharmaceuticals, Alembic Pharmaceuticals, InvaGen Pharmaceuticals Inc., SiteOne Therapeutics, Pfizer Inc., and others.
Post-Surgical Pain Marketed and Emerging Therapies Profile:
-
Dsuvia/Dzuveo (Sufentanil): AcelRx Pharmaceuticals
-
Olinvyk (Olinvo) (oliceridine): Trevena, Inc.
-
Zynrelef (HTX-011): Heron Therapeutics
-
VVZ-149 Injections: Vivozon, Inc.
-
TPU-006 (Dexmedetomidine Transdermal System (DMTS)): Teikoku Pharma USA, Inc.
-
NVK-009 (Pregabalin and Acetaminophen): Nevakar, Inc.
-
TLC590: Taiwan Liposome Company (TLC)
-
OCS-01: Oculis
-
PRF110: PainReform LTD
-
Vocacapsaicin (CA-008): Concentric Analgesics
Report Covers the In-depth Assessment of the Emerging Drugs & Key Companies. Download the Sample Report to Learn More @ https://www.delveinsight.com/sample-request/post-surgical-pain-market
Table of Contents
1. Key Insights
2. Executive Summary
3. Post-Surgical Pain Competitive Intelligence Analysis
4. Post-Surgical Pain Market Overview at a Glance
5. Post-Surgical Pain Disease Background and Overview
6. Post-Surgical Pain Patient Journey
7. Post-Surgical Pain Epidemiology and Patient Population (In the US, EU5, and Japan)
8. Post-Surgical Pain Treatment Algorithm, Current Treatment, and Medical Practices
9. Post-Surgical Pain Unmet Needs
10. Key Endpoints of Post-Surgical Pain Treatment
11. Post-Surgical Pain Marketed Products
12. Post-Surgical Pain Emerging Drugs and Latest Therapeutic Advances
13. Post-Surgical Pain Seven Major Market Analysis
14. Attribute Analysis
15. Post-Surgical Pain Market Outlook (In US, EU5, and Japan)
16. Post-Surgical Pain Access and Reimbursement Overview
17. KOL Views on the Post-Surgical Pain Market
18. Post-Surgical Pain Market Drivers
19. Post-Surgical Pain Market Barriers
20. Appendix
21. DelveInsight Capabilities
22. Disclaimer
Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Kritika Rehani
Email: Send Email
Phone: +14699457679
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: Nevada
Country: United States
Website: https://www.delveinsight.com/